MDC
Asset Logo

Medlab Clinical Limited

🇦🇺 ASX

Compare
Add to watchlist
👑 Overview

📈 Performance

💵 Cost

🤓 Advanced

👨‍👩‍👧‍👦 Community

📈

N/A
Annual Growth

5 years average annual capital growth

💵

$ 500
Minimum Order

Due to regulatory requirements

🌏

4
Pearlers Invested

Since January 2020

👑 Overview

Key information
🔎 Fund Overview

Medlab Clinical Ltd. engages in the development of therapeutic pathways for diagnosed chronic diseases. The company is headquartered in Alexandria, New South Wales. The company went IPO on 2015-07-14. The firm is investigating a range of prescription and non-prescription solutions for unmet patient needs across a variety of therapeutic areas, including pain management, mental health, gut health, diabetes, and allergies. The Company’s drug candidates include NanaBis, NanoCBD and NanoCelle. Medlab’s pipeline comprises a range of small and large molecules from repurposing generic medicines to enhancing the delivery of immunotherapies. The firm's lead drug candidate, NanaBis, is under development for cancer bone pain as an alternative to opioid use and NanoCBD for mental stress . The firm also has a drug delivery platform called NanoCelle, which is wholly owned by Medlab and developed in Medlab’s owned Office of the Gene Technology Regulator (OGTR) registered laboratory.

📈 Performance

Price History

-78.00%

1M

All Time

Graph

Table

Unsure how much or often to invest?
🗓️ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out →
💵 Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out →
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out →

💵 Costs

💵

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

💼

N/A
Management Fee

Included in unit price, not charged by Pearler

💸

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator

🤓 Advanced information

Technical Info

💰 Price*

$6.60

*Price may be up to 24 hours old

👩‍👩‍👦 Community Insights

How our community is investing

🌏 Pearlers invested in MDC

4

📊 Total Capital Earnings

N/A

🔃 Average investment frequency

N/A

💵 Average investment amount

N/A

Last time a customer invested in MDC

1094 days
MDC investor breakdown
💵 Income of investors

More than 200k

150k - 200k

100k - 150k

50k - 100k

50%

Less than 50k

50%
👶 Age of investors

18 - 25

25%

26 - 34

25%

35 - 90

50%
🙋 Legal gender of investors

Female

75%

Male

25%

Pearlers who invest in MDC also invest in...

Vanguard Us Total Market Shares Index Etf

VTS

VTS.AX was created on 2009-05-12 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard U.S. Total Market Shares Index ETF seeks to track the performance of the CRSP US Total Market Index, providing investors with exposure to a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.

📊 Share price

$320.13 AUD

NULL US

NULL EX AUSTRALIA

NULL BETA

Find Out More

Orthocell Ltd. engages in the development and commercialization of cell therapies and related technologies. The company is headquartered in Perth, Western Australia. The company went IPO on 2014-08-12. The firm is focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Its portfolio of products includes CelGro, Striate+, Remplir, and SmrtGraft. CelGro is a collagen medical device that facilitates tissue reconstruction and healing in a variety of dental and orthopedic reconstructive applications. CelGro is manufactured using a SMRT manufacturing process to preserve the natural collagen structure. Striate+ is used for dental GBR applications. Remplir is for peripheral nerve reconstruction. SmrtGraft is for tendon repair. Its other major products are autologous cell therapy, which focuses on regenerating damaged tendon and cartilage tissue. The company is engaged in the development of its tendon cell therapy in the United States. Its autologous tendon therapy is an advanced injectable cellular therapy for the treatment of chronic tendon injuries.

📊 Share price

$0.37 AUD

VDHG

VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.

📊 Share price

$57.36 AUD

NULL GLOBAL

NULL SMART BETA

A200

A200.AX was created on 2018-05-07 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The ETF currently has 2975.21m in AUM and 200 holdings. A200.AX aims to track the performance of an index (before fees and expenses) comprising 200 of the largest companies by market capitalisation listed on the ASX.

📊 Share price

$120.79 AUD

NULL AUSTRALIA

NULL BETA

Qantas Airways Ltd. provides air transportation services. The company is headquartered in Mascot, New South Wales. The firm is focused on the operation of international and domestic air transportation services, the provision of freight services, and the operation of a frequent flyer loyalty program. The firm's segments include Qantas Domestic, Qantas International, Jetstar Group and Qantas Loyalty. The Qantas Domestic, Qantas International, and Jetstar Group are engaged in passenger flying business and air cargo and express freight businesses. The Qantas Loyalty segment is engaged in the customer loyalty recognition programs. Its main business is the transportation of customers using two airline brands, which include Qantas and Jetstar. Its airline brands operate in regional, domestic and international services. The firm operates in Australia, New Zealand, South Pacific, Asia, Europe, North and South America, and Africa.

📊 Share price

$6.51 AUD

NULL AIRLINES

Want more shares? Try these...

📊 Share price

$12.90 AUD

Mercury NZ Ltd. engages in the generation and distribution of electricity from hydro, geothermal, and gas. The firm generates electricity from renewable resources, such as hydro, geothermal and wind. Its products and services consist of generation/wholesale and retail. Generation/wholesale market segment encompasses activity associated with electricity generation, electricity trading, generation development activities. The company is engaged in sale of electricity to both commercial and industrial customers and the retail segment. Retail segment encompasses activity associated with sale of energy, and related services, to customers in New Zealand. The retail operations serve commercial and residential (small medium sized businesses) customers. The company offers pre-pay electricity product, GLOBUG. The company manages several subsidiary enterprises, such as its EV Subscription Service. The firm is also engaged in the business of gas, telecommunications business, and retail electricity supply business.

📊 Share price

$5.99 AUD
Compare
Add to watchlist